[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese Pulmonary Vascular Disease Research Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":184},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,38,61,97,123,143,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100636817","development-and-validation-of-a-chinese-quality-of-life-scale-for-pulmonary-arterial-hypertension-100636817",false,"NCT07570615","Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension","Development and Validation of a Chinese Patient-Reported Outcome Measure for Quality of Life in Pulmonary Arterial Hypertension Patients","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed with pulmonary arterial hypertension\n* Able to read and complete questionnaires\n* Provided informed consent\n\nExclusion Criteria:\n\n* Severe physical condition preventing participation\n* History of psychiatric disorders or current use of psychiatric medication\n* Pregnancy or lactation\n* Any condition preventing completion of questionnaires","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in China.\n\nThe study includes two phases: (1) scale development using literature review, Delphi expert consultation, and patient interviews; and (2) multicenter prospective observational validation to evaluate reliability, validity, and responsiveness.\n\nThe final scale is expected to support clinical assessment, treatment monitoring, and health policy decision-making.",[24,25,26],"Pulmonary Arterial Hypertension (PAH)","Quality of Life","Patients Reported Outcomes","NOT_YET_RECRUITING","2026-04-30",{"date":30,"type":31},"2026-05-06","ACTUAL",{"date":28,"type":20},{"date":34,"type":20},"2029-04-30",{"name":36,"class":37},"Chinese Pulmonary Vascular Disease Research Group","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":45,"conditions":46,"keywords":49,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100629992","portosystemic-shunt-associated-pulmonary-hypertension-multi-center-prospective-cohort-study-100629992","NCT07481877","Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of Portosystemic Shunts:Imaging evidence suggestive of portosystemic shunts (congenital or acquired) or unequivocal clinical signs of portal hypertension (e.g., splenomegaly, varices).\n3. Diagnosis of Pulmonary Hypertension (PH):\n\n   * Confirmed by Right Heart Catheterization (RHC): mPAP \\> 20 mmHg; OR\n   * Highly suspected by Echocardiography: Peak TRV \\> 3.4 m\u002Fs or compliant with ESC\u002FERS guidelines for high probability of PH (Note: RHC is encouraged for all enrolled patients).\n4. Signed informed consent and willingness to strictly adhere to the follow-up schedule.\n\nExclusion Criteria:\n\n1. PH caused by other reasons\n2. Hepatocellular carcinoma (HCC) exceeding the Milan criteria.\n3. Active extrahepatic malignancy.\n4. Transjugular intrahepatic portosystemic shunt (TIPS) placement within the previous month.\n5. Pregnancy or lactation.\n6. Participation in other interventional clinical trials (drug or device) within the last 3 months.",{"count":19,"type":20},"This study aims to establish a multi-center registry cohort of portosystemic shunt-associated pulmonary hypertension, with the goal of clarifying the epidemiology, clinical features, phenotypic classification, response to targeted therapy, and prognostic outcomes in patients with portosystemic shunt-associated pulmonary hypertension.",[47,48],"Portosystemic Shunt","Pulmonary Hypertension",[47,48,50,51,52],"POPH","Portal hypertension","Cirrhosis","2026-03-13",{"date":55,"type":31},"2026-03-19",{"date":57,"type":20},"2026-04-01",{"date":59,"type":20},"2031-04-01",{"name":36,"class":37},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100482743","artificial-intelligence-assisted-evaluation-of-pulmonary-hypertension-100482743","NCT05566002","Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension","Artificial Intelligence-Assisted Evaluation of Pulmonary Hypertension","AIPHY","Inclusion Criteria:\n\n* Age ≥18 years old\n* Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \\& PUMC, Beijing, China\n\nExclusion Criteria:\n\n* Patients without RHC\n* The quality of routine examinations and RHC cannot meet the requirement for further analysis\n* Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)",true,{"count":71,"type":20},2000,"Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.",[48,74],"Pulmonary Arterial Hypertension",[76,77,78,79,80,81,82,83,84,85,86],"pulmonary hypertension","pulmonary vascular disease","right heart catheterization","echocardiography","electrocardiography","chest X-ray","artificial intelligence","machine learning","deep learning","screening","diagnosis","RECRUITING","2025-04-06",{"date":90,"type":31},"2025-04-08",{"date":92,"type":31},"2022-06-01",{"date":94,"type":20},"2025-12-31",{"name":36,"class":37},1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":69,"sex":16,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":104,"studyType":21,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":96},"100213915","the-application-of-cardiopulmonary-exercise-testing-in-assessment-outcome-of-patients-with-pulmonary-hypertension-100213915","NCT02061787","the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension","CPETPH","Inclusion Criteria:\n\n* pulmonary arterial hypertension;( WHO1)\n* chronic thromboembolic pulmonary hypertension;\n* pulmonary arterial hypertension due to other cause;\n\nExclusion Criteria:\n\n* massive hemoptysis;\n* unable to accomplish cardiopulmonary exercise testing due to neuromuscular disorders;\n* recent recurrent syncope;\n* pulmonary hypertension due to hypoxia;\n* pulmonary hypertension due to left heart diseases.","5 Years","100 Years",{"count":107,"type":20},4000,"cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment",[48,110,111],"Chronic Thromboembolic Pulmonary Hypertension","Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)",[110,74,113,114],"balloon pulmonary angioplasty","cardiopulmonary exercise test","2024-09-09",{"date":117,"type":31},"2024-09-19",{"date":119,"type":31},"2010-09",{"date":121,"type":20},"2030-09-08",{"name":36,"class":37},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":104,"studyType":21,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":96},"100526528","chase-registry-of-patients-with-pulmonary-hypertension-receiving-targeted-therapy-100526528","NCT06135909","CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy","CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy","Inclusion Criteria:\n\n* Sign informed consent;\n* Between the ages of 18 and 85;\n* Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).\n\nExclusion Criteria:\n\n* Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;\n* Patients with malignant tumor and other diseases and life expectancy of less than half a year;\n* Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension","85 Years",{"count":132,"type":20},5000,"CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)",[48],"2024-01-16",{"date":137,"type":31},"2024-01-18",{"date":139,"type":31},"2020-01-01",{"date":141,"type":20},"2027-12-31",{"name":36,"class":37},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":96},"100469121","treatment-of-patients-with-takayasu-arteritis-complicated-with-pulmonary-artery-involvement-100469121","NCT05388682","Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement","Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement","Inclusion Criteria:\n\n* patients diagnosed with Takayasu arteries with pulmonary arteries involvement\n\nExclusion Criteria:\n\n* Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis",{"count":151,"type":20},200,"1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement\n2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement",[154,155,156],"Takayasu Arteritis With Pulmonary Artery Involvement","Percutaneous Transluminal Pulmonary Angioplasty","PAH Targeted Medication",[158],"Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement","2023-12-14",{"date":161,"type":31},"2023-12-20",{"date":163,"type":31},"2014-01-19",{"date":165,"type":20},"2042-12-31",{"name":36,"class":37},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":174,"studyType":21,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},"100378384","safety-and-efficacy-of-balloon-pulmonary-angioplasty-in-china-100378384","NCT04206852","Safety and Efficacy of Balloon Pulmonary Angioplasty in China","Inclusion Criteria:\n\n1. diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP \\\u003C 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines\n2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH\n3. Not amenable to pulmonary endarterectomy\n4. Willing to provide informed consent\n\nExclusion Criteria:\n\n1. Patients unwilling or unable to provide written consent for participation in the study.\n2. Impossible to follow up.",{"count":151,"type":20},"4 Years","Balloon pulmonary angioplasty (BPA) is a potential treatment for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH).\n\nThe aim of this study was to evaluate the safety and efficacy of BPA in CTEPH patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA.",[110],{"date":161,"type":31},{"date":179,"type":31},"2018-05-11",{"date":181,"type":20},"2028-05-11",{"name":36,"class":37},2,""]